SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbrdn Di&g Regulatory News (ADIG)

  • This share is currently suspended. It was suspended at a price of 13.33

Share Price Information for Abrdn Di&g (ADIG)

Share Price is delayed by 15 minutes
Get Live Data
13.33    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £40.16m
ADIG Live PriceLast checked at - London Stock Exchange

Intraday Abrdn Di&g Share Chart

Update on Managed Wind Down

18 Dec 2025 15:00

RNS Number : 1744M
abrdn Diversified Income and Growth
18 December 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR"). ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THE JURISDICTION.

18 December 2025

For Immediate Release

ABRDN DIVERSIFIED INCOME AND GROWTH PLC

(the "Company")

 

Update on Managed Wind-Down

The Company confirms that it has completed, or shortly expects to complete, the sales of a further four of its fund investments and private market assets ("Fund Interests") raising approximately ÂŁ3.4 million of gross consideration and unlocking approximately ÂŁ0.7 million of cash being retained in respect of the Company's undrawn commitments(1), pursuant to the Company's managed wind-down.

Update on completed secondary sales

As set out in the announcement made by the Company on 1 October 2025 (the "1 October Announcement"), the Company has conducted a comprehensive marketing exercise in respect of its Fund Interests pursuant to a secondary sales process (the "Secondary Sales Process").

As the Company announced on 29 October 2025, the Company has already completed a number of initial secondary sales, the net proceeds of which were returned to shareholders (together with the proceeds of the redemption of the Company's interest in the Aberdeen Global Private Markets Fund and part of the Company's other cash reserves) pursuant to a ÂŁ57.2 million return of capital in November 2025. As noted above, the Company has now completed the sale and transfer of an additional four Fund Interests.

Of these newly completed sales, two Fund Interests were sold pursuant to the signed sale and purchase agreements referenced in the 1 October Announcement.(2) Such assets were valued at approximately ÂŁ1.4 million as at 31 October 2025 (equivalent to approximately 0.5 pence per share), which represented approximately 0.8 per cent. of the Company's net asset value ("NAV") on that date. As previously reported, in the light of the contractually agreed pricing, such assets were being carried by the Company at the agreed sale price (without adjustment for transaction costs).

In line with the pricing expected for these assets at the time of the 1 October Announcement, the two further recently concluded sales were completed with other third parties for gross consideration of approximately ÂŁ2.1 million (before adjustment for transaction costs). Such Fund Interests were valued at approximately ÂŁ3.6 million as at 31 October 2025 (equivalent to approximately 1.2 pence per share), which represented approximately 2.1 per cent. of the Company's NAV on that date.

Future returns to shareholders

The Board remains committed to returning the net proceeds of any realisations to shareholders progressively in an efficient and fair manner. As part of its assessment, the Board will give due consideration to the expected timeline for the managed wind-down and the costs of returning funds to shareholders. The Board currently expects the Company will complete a number of further secondary sales of the remaining Fund Interests in the coming month. The Board will provide further updates, as appropriate, in due course.

In the light of the progress with the Secondary Sales Process, the Board remains on track to put forward proposals in Q1 2026 to place the Company into members' voluntary liquidation. With that said, there can be no certainty as to the precise quantum or timing for the completion of any further realisations or returns of capital arising out of or in connection with the Secondary Sales Process.

November NAV

The Company's next NAV announcement will be calculated as at 30 November 2025 and will be published following the Company's interim report for the six month period ended 30 September 2025. In the light of the advanced stage of negotiations in respect of the secondary sales of the Company's remaining Fund Interests, the Board and the Company's investment manager (the "Manager") intend to adjust the valuation of the Fund Interests reported by the underlying general partners / managers of the Fund Interests to reflect the value that is expected to be achieved from the sales of such Fund Interests pursuant to the Secondary Sales Process for the purposes of the November NAV announcement.

Enquiries:

abrdn Diversified Income and Growth plc

Davina Walter (Chairman) via Burson Buchanan

Dickson Minto Advisers LLP

Douglas Armstrong / Andrew Clark / Jamie Seedhouse +44 (0)20 7649 6823

Burson Buchanan

Helen Tarbet / Henry Wilson / Nick Croysdill +44 (0)20 7466 5000

ADIG@buchanancomms.co.uk

Notes:

(1) Includes any capital distributions received by the Company in respect of the relevant Fund Interests that could have been recalled.

(2) As set out in the 1 October Announcement, the Company agreed terms for the proposed sales in respect of 15 Fund Interests (which included the sales of 50 per cent. of the Company's interest in two Fund Interests). Of these 15 sales, five have completed as at, or are expected to be completed on, the date of this announcement.

Important information

This announcement is released by the Company and the information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Article 7 of UK MAR. Upon publication of this announcement via a Regulatory Information Service, such information is now considered to be in the public domain. The person responsible for arranging for the release of this announcement on behalf of the Company is abrdn Holdings Limited, the Company Secretary.

The Company's LEI number is 2138003QINEGCHYGW702.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBSBDDRSBDGUI
Date   Source Headline
6th Dec 20241:43 pmRNSNet Asset Value(s)
5th Dec 20244:06 pmRNSCircular and Notice of General Meeting
5th Dec 20243:21 pmRNSMonth End Net Asset Value(s)
5th Dec 202412:21 pmRNSNet Asset Value(s)
4th Dec 20241:06 pmRNSNet Asset Value(s)
3rd Dec 202412:19 pmRNSNet Asset Value(s)
29th Nov 202412:31 pmRNSNet Asset Value(s)
28th Nov 20241:13 pmRNSNet Asset Value(s)
27th Nov 202412:11 pmRNSNet Asset Value(s)
26th Nov 20242:24 pmRNSNet Asset Value(s)
25th Nov 202412:40 pmRNSNet Asset Value(s)
22nd Nov 20241:14 pmRNSNet Asset Value(s)
21st Nov 202412:33 pmRNSNet Asset Value(s)
20th Nov 202412:12 pmRNSNet Asset Value(s)
19th Nov 20241:08 pmRNSNet Asset Value(s)
18th Nov 20241:18 pmRNSNet Asset Value(s)
15th Nov 20241:04 pmRNSNet Asset Value(s)
14th Nov 202412:25 pmRNSNet Asset Value(s)
13th Nov 202412:43 pmRNSNet Asset Value(s)
12th Nov 202412:05 pmRNSNet Asset Value(s)
11th Nov 20241:24 pmRNSNet Asset Value(s)
8th Nov 202412:30 pmRNSNet Asset Value(s)
7th Nov 20241:58 pmRNSNet Asset Value(s)
6th Nov 20241:36 pmRNSNet Asset Value(s)
6th Nov 202411:29 amRNSMonth End Net Asset Value(s)
5th Nov 20241:45 pmRNSNet Asset Value(s)
4th Nov 202412:31 pmRNSNet Asset Value(s)
31st Oct 202412:38 pmRNSNet Asset Value(s)
30th Oct 202412:13 pmRNSNet Asset Value(s)
29th Oct 202412:41 pmRNSNet Asset Value(s)
28th Oct 202411:59 amRNSNet Asset Value(s)
25th Oct 202412:11 pmRNSNet Asset Value(s)
25th Oct 20247:00 amRNSCompliance with Market Abuse Regulation
24th Oct 202412:29 pmRNSNet Asset Value(s)
23rd Oct 20242:07 pmRNSNet Asset Value(s)
22nd Oct 202412:31 pmRNSNet Asset Value(s)
21st Oct 20241:22 pmRNSNet Asset Value(s)
21st Oct 202410:18 amRNSDirector Declaration
18th Oct 202412:08 pmRNSNet Asset Value(s)
17th Oct 202412:05 pmRNSNet Asset Value(s)
16th Oct 202411:37 amRNSNet Asset Value(s)
15th Oct 202411:48 amRNSNet Asset Value(s)
14th Oct 202412:10 pmRNSNet Asset Value(s)
11th Oct 202411:33 amRNSNet Asset Value(s)
10th Oct 202412:39 pmRNSNet Asset Value(s)
9th Oct 202412:29 pmRNSNet Asset Value(s)
8th Oct 202412:32 pmRNSNet Asset Value(s)
7th Oct 202412:17 pmRNSNet Asset Value(s)
4th Oct 20242:29 pmRNSNet Asset Value(s)
4th Oct 202411:09 amRNSMonth End Net Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.